Detailed price information for Philip Morris International Inc (PM-N) from The Globe and Mail including charting and trades.

Own stocks of companies that get drugs approved. That hasn’t been so easy. But the U.S. Food & Drug Administration (FDA) has ...

If you've experienced serious side effects from Oxbryta, find out if you qualify for compensation. CHEYENNE, WY / ACCESSWIRE / October 23, 2024 / InjuryClaims.com is connecting people who may have ...

The study's design and endpoints have been crafted to support full approval, distinguishing it from the development path of competitor drugs like Oxbryta. The SCD market has become increasingly ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

FILE PHOTO: Jeffrey Smith, Managing Member, CEO and CIO of Starboard Value, speaks during the 13D Monitor's Active-Passive Investor Summit in New York City, U.S., October 18, 2022. REUTERS/Brendan ...

Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to the onset of a vaso-occlusive crisis (VOC) as ...

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...